Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
26 hedge funds and large institutions have $15.1M invested in Medicenna Therapeutics Corp. Common Shares in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 9 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
16% less funds holding
Funds holding: 31 → 26 (-5)
34% less capital invested
Capital invested by funds: $22.9M → $15.1M (-$7.83M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$277K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$134K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
+$93K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$89.5K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$63.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$2.15M |
| 2 |
Millennium Management
New York
|
-$500K |
| 3 |
Renaissance Technologies
New York
|
-$402K |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$402K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$328K |
MDNA Hedge Fund Activity: Q2 2021 in Review
26 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q2 2021, worth a combined $15.1M — down 34% from $22.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of MDNA and 4 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 13 added.
The largest buyer was AIGH Capital Management, adding an estimated $277K. The largest seller was Janus Henderson Group, exiting entirely with an estimated $2.15M sold.
- 26 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q2 2021, down from 31 in Q1 2021.
- Funds reported $15.1M of Medicenna Therapeutics Corp. Common Shares stock for Q2 2021, down 34% quarter-over-quarter.
- 4 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q2 2021 and 9 closed out, a net change of -5 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q2 2021 was AIGH Capital Management, an estimated $277K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q2 2021 was Janus Henderson Group, an estimated $2.15M sold.
Based on aggregated 13F filings for Q2 2021.